UNIQURE N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.76 USD | 0.00% |
|
-4.99% | -29.69% |
| May. 08 | Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating | MT |
| May. 07 | UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 47.23M 51.22M | Sales 2025 * | 83.38M 90.43M | Capitalization | 213M 231M |
|---|---|---|---|---|---|
| Net income 2024 * | -220M -239M | Net income 2025 * | -171M -185M | EV / Sales 2024 * | 3.04 x |
| Net cash position 2024 * | 69.35M 75.21M | Net Debt 2025 * | 9.03M 9.79M | EV / Sales 2025 * | 2.66 x |
| P/E ratio 2024 * |
-1.02
x | P/E ratio 2025 * |
-1.27
x | Employees | 480 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.72% |
More Fundamentals
* Assessed data
More news
Latest transcript on uniQure N.V.
More recommendations
More press releases
| 1 week | -4.99% | ||
| Current month | +7.94% | ||
| 1 month | +4.39% | ||
| 3 months | -24.68% | ||
| 6 months | -30.81% | ||
| Current year | -29.69% |
1 week
4.69
5.09
1 month
4.255.19
Current year
4.257.12
1 year
4.2521.00
3 years
4.2538.80
5 years
4.2582.49
10 years
4.2582.49
| Managers | Title | Age | Since |
|---|---|---|---|
Matt Kapusta
CEO | Chief Executive Officer | 51 | 14-12-31 |
Christian Klemt
DFI | Director of Finance/CFO | 51 | 14-12-31 |
Pierre Caloz
COO | Chief Operating Officer | 52 | 21-05-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonard Post
BRD | Director/Board Member | 72 | 20-06-16 |
Jack Kaye
BRD | Director/Board Member | 80 | 16-06-14 |
| Director/Board Member | 61 | 17-09-13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.96% | 11 M€ | -6.03% | - | |
| 0.76% | 14 M€ | -5.30% | ||
| 0.48% | 28 M€ | -1.64% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 4.76 | 0.00% | 225,744 |
| 24-05-23 | 4.76 | -5.56% | 469,896 |
| 24-05-22 | 5.04 | +5.00% | 718,710 |
| 24-05-21 | 4.8 | -1.03% | 499,816 |
| 24-05-20 | 4.85 | -3.19% | 524,633 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotes
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Companyâs lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntingtonâs disease is in Phase I/II clinical study.
Calendar
2024-06-18
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
4.385
EUR
Average target price
18.07
EUR
Spread / Average Target
+311.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.69% | 231M | |
| +12.30% | 116B | |
| +12.15% | 106B | |
| -8.14% | 23.89B | |
| -1.69% | 21.58B | |
| -10.60% | 18.96B | |
| -41.25% | 16.96B | |
| -15.33% | 16.33B | |
| +5.80% | 14.14B | |
| +28.03% | 12.02B |
- Stock Market
- Equities
- QURE Stock
